



IOL CHEMICALS AND PHARMACEUTICALS LIMITED

IOLCP/CGC/2023
28th April 2023

National Stock Exchange of India Ltd.
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400 051
Security Symbol: IOLCP

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street
Mumbai- 400 001
Security Code: 524164

Subject: Press Release - Financial Results for the quarter and year ended 31st March 2023

Dear Sir,

Please find enclosed herewith press release regarding Financial Results for the quarter and year ended 31st March 2023.

Hope you will find the same in order.

Thanking You,

Yours faithfully,
For IOL Chemicals and Pharmaceuticals Limited

Abhay Raj Singh
Vice President & Company Secretary

For immediate release

IOL Chemicals and Pharmaceuticals reports strong Q4FY23 results

Q4 FY23 Financial Highlights

- Total income for Q4 FY23 stood at Rs. 596 crore as against Rs. 530 crore in Q3 and Rs.579 crore YoY
- EBITDA for Q4 FY23 at Rs. 104 crore as compared to Rs. 50 crore in Q3 and Rs. 50 crore YoY
- Net profit for Q4 FY23 at Rs. 65 crore as compared to Rs. 24 crore in Q3 FY23 and Rs. 28 crore YoY

FY23 Financial Highlights

- Total income for FY23 stood at Rs. 2,243 crore as compared to Rs. 2,216 crore in FY22
- EBITDA for FY23 at Rs. 252 crore as compared to Rs. 288 crore in FY22
- Net profit for FY23 at Rs. 140 crore as compared to Rs. 166 crore in FY22

28th April 2023, Ludhiana:

IOL Chemicals and Pharmaceuticals Ltd, a leading manufacturer of pharmaceutical APIs and speciality chemicals, announced its financial results for the fourth quarter and fiscal year ended March 31, 2023.

Q4FY23 Financial Highlights

(Rs in Crore)

Particulars	Quarterly					Yearly		
	Q4FY23	Q3FY23	% QoQ	Q4FY22	% YoY	FY23	FY22	% YoY
Total Income	595.9	530.1	12.4%	579.4	2.9%	2242.7	2,216.1	1.2%
EBITDA	104.5	49.7	110.3%	50.0	108.8%	252.1	288.3	-12.6%
EBITDA Margin (%)	17.5%	9.4%	↑ 810 bps	8.6%	↑ 890 bps	11.2%	13.0%	↓ 180 bps
PAT	65.3	24.2	169.8%	27.7	135.2%	140.0	165.7	-15.5%
PAT Margin (%)	11.0%	4.6%	↑ 640 bps	4.8%	↑ 620 bps	6.2%	7.5%	↓ 130 bps

Commenting on the performance, Mr Vikas Gupta, Joint Managing Director said, “The last quarter of the financial year has come out strong for us as we stabilized our operations in pharma and speciality chemicals segments with a focus on cost rationalisation and margin improvement.

With significant operational, technical and commercial efficiencies, improved market combination and expecting sustainable demand as an alternative to China, we believe we are on a good upward trajectory.

About IOL Chemicals and Pharmaceuticals Limited (IOLCP)

Established in 1986 and listed on the National Stock Exchange of India Ltd (Code: IOLCP) and BSE Ltd (Code: 524164), IOL Chemicals and Pharma is one of the leading pharmaceutical (APIs) Companies and a significant player in the specialty chemicals space with world-class facilities. IOLCP has a wide presence across major therapeutic categories like Pain Management, anti-convulsants, anti-diabetes, anti-cholesterol and anti-platelets.

The Company's product portfolio includes APIs; Ibuprofen, Metformin, Fenofibrate, Clopidogrel, Lamotrigine, Pantoprazole, Paracetamol and specialty chemicals such as Ethyl Acetate, Iso Butyl Benzene, Mono Chloro Acetic Acid and Acetyl Chloride.

The company is the World's largest producer of Ibuprofen with an installed capacity of 12,000 TPA and having backward integrated manufacturing facility. The Company has DSIR-approved R&D which is fully equipped to validate existing processes.

The Central and State Government approved Effluent Treatment Plant (ETP) had been set up with Zero Liquid Discharge (ZLD) system along with a 17 MW captive Co-Generation plant for self-reliance. The Company is ISO 9001:2015, 14001:2015 and BS OHSAS 18001:2007 certified.

IOLCP's overseas customers are spread out across several countries including the UK, Belgium, Hungary, Spain, Germany, Italy, Netherlands, Switzerland, Poland, Ireland, USA, Peru, Brazil, Argentina, Colombia, Indonesia, South Korea, Thailand, Bangladesh, Turkey, U.A.E., China, Hong Kong, Egypt etc. Products are sold primarily to Branded Generic formulators both in India & Overseas.

Disclaimer:

This document may contain statements which reflect management's current views and estimates and could be construed as forward-looking statements. The future involves certain risks and uncertainties and could cause actual results to differ materially from the current views being expressed. Potential risks and uncertainties include factors such as general economic conditions, foreign exchange fluctuation, pricing pressures, competition and regulatory developments.